I型变态反应性疾病 ,包括哮喘、过敏性鼻炎、特应性皮炎及食物过敏等 ,在过去的 2 0年中发病率逐年上升 ,全世界约有 1.0～ 1.5亿人患有哮喘 ,每年可导致约 18万人死亡[1] 。估计全球为防治哮喘的经济代价已超过用于结核病和艾滋病的总和[2 ] 。目前 ,比较成熟的抗过敏疗法及脱 Type I allergic diseases, including asthma, allergic rhinitis, atopic dermatitis and food allergies, have been increasing year by year with an estimated 110 to 150 million people worldwide with asthma each year Resulting in about 180,000 deaths [1]. It is estimated that the global economic costs of preventing and treating asthma have surpassed those used for tuberculosis and AIDS [2]. At present, the more mature anti-allergy therapy and off